Diligence memo · auto-generated · as of July 2, 2026
Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Immune Response BioPharma, Inc. operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immune Response BioPharma, Inc. has raised $1.0B in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $1.0B on —.
Valuation (modeled)modeled
Provath models Immune Response BioPharma, Inc. at approximately $7.6B (range $6.6B–$8.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.44× the median modeled value of Growth/Late Pharmaceuticals companies (14 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
No dated round to assess.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.